Neoadjuvant treatment with trastuzumab in HER2-positive . . . PURPOSE Trastuzumab, a humanized antibody against the human epidermal growth factor receptor type 2 (HER2), has shown high efficacy in breast cancer We prospectively investigated its efficacy given simultaneously with anthracycline-taxane-based neoadjuvant chemotherapy
Survival Analysis After Neoadjuvant Chemotherapy With . . . The neoadjuvat GeparQuinto phase III study compared two anti-HER2–targeted agents, lapatinib versus trastuzumab, in combination with chemotherapy for treatment of HER2-positive primary breast cancer
Neoadjuvant therapy for locally advanced breast cancer: Focus . . . Despite progress achieved in diagnosis and therapy in recent years, locally advanced breast cancer (LABC) remains a major clinical issue Biological characteristics and clinical behavior varies widely, ranging from indolent to locally aggressive or generalized disease
Treatment of locally recurrent and advanced breast cancer Breast cancer is primarily subtyped according to the hormone and HER2 receptor status of the tumour In locally advanced and metastatic breast cancer, this subtyping influences first line and subsequent systemic treatments and helps with prognostication
Neoadjuvant Treatment With Trastuzumab in HER2-Positive . . . Trastuzumab, a humanized antibody against the human epidermal growth factor receptor type 2 (HER2), has shown high efficacy in breast cancer We prospectively investigated its efficacy given simultaneously with anthracycline-taxane–based neoadjuvant chemotherapy